Does Assyro provide Evaluate Pharma consensus forecasts?

No. Assyro's supported public-record research does not provide Evaluate's proprietary commercial forecast or deal dataset.

Where does Ask Ella get its answers?

Evaluate's current page says Ella uses licensed datasets inside the subscribed product and traces results to underlying records. Confirm the exact subscription and entitlement rather than assuming open-web or whole-portfolio access.

Is a cited sales forecast a reported result?

No. Retain its forecast vintage, horizon, geography, currency and assumptions. Label forecasts separately from reported sales and later realized outcomes.

Is Ask Ella the same as Norstella Atlas CI?

The current vendor FAQ distinguishes them. Ella is product-specific; Atlas CI is described separately. Ask which product and data scope the proposal includes.

Comparison/Updated October 2026

Assyro Intelligence vs Evaluate Pharma

Compare the data behind a commercial conclusion: public evidence, licensed forecasts, historical revisions and explicit assumptions.

Assyro Intelligence

by Assyro AI

Public-source life-science research with citations and scheduled watches.

Assyro Intelligence

Cited public eventsTrial/regulatory contextScheduled watchesFree to start

Evaluate Pharma

Commercial biopharma forecasts and market intelligence

Commercial intelligence and consensus forecasts, with Ask Ella for licensed-product queries.

Consensus forecastsCommercial benchmarksDeal/patent dataAsk Ella

The verdict

Evaluate Assyro Intelligence for cited research and watches on supported public regulatory, trial, literature and disclosed company records. Evaluate Evaluate Pharma when consensus sales forecasts, deal/patent intelligence or commercial asset benchmarks are essential. Assyro does not supply that licensed forecast and deal dataset. Ask Ella is grounded in the licensed data inside the subscribed Evaluate product; it is not an interchangeable open-web research assistant. A sourced forecast remains an estimate, not a reported fact or guaranteed outcome.

Written individually by Assyro AI, a compared vendor. Current Evaluate Pharma, Ask Ella and pricing pages checked October 13, 2026. This is dataset/application scope analysis; no forecast-accuracy, investment-performance or answer-speed benchmark was executed.

Separate public events from commercial estimates

The right product depends on which missing input the research needs.

Evidence and data boundaries
Question	Assyro	Evaluate Pharma
What was publicly disclosed?	Supported cited records	Qualify event source
What is consensus future sales?	Outside proprietary scope	Forecast dataset
What are commercial deal benchmarks?	Disclosed facts only	Licensed deal data
What can AI query?	Supported public sources	Subscribed product records via Ella

What was publicly disclosed?
Assyro
Supported cited records
Evaluate Pharma
Qualify event source
What is consensus future sales?
Assyro
Outside proprietary scope
Evaluate Pharma
Forecast dataset
What are commercial deal benchmarks?
Assyro
Disclosed facts only
Evaluate Pharma
Licensed deal data
What can AI query?
Assyro
Supported public sources
Evaluate Pharma
Subscribed product records via Ella

[1][2][4]

A commercial narrative needs transparent assumptions

An approval, trial result or disclosed milestone can inform a commercial view without proving future sales. Preserve the original event and the assumptions connecting it to your forecast or strategy.

Use Assyro where supported public-source research supplies the evidence. Select Evaluate where a licensed commercial dataset is indispensable, and test that dataset's identifiers, vintages and definitions before relying on the assistant's summary.

Feature by feature

Published capabilities, related applications and evidence still to request.

Public regulatory/company evidence
Assyro Intelligence
Supported source-cited research[4]
Evaluate Pharma
Qualify underlying events in the licensed product[1]
Consensus commercial forecasts
Assyro Intelligence
Proprietary consensus forecasts are not offered[4]
Evaluate Pharma
Named Evaluate Pharma forecast dataset[1]
Deal and patent benchmarks
Assyro Intelligence
Public disclosures only; no proprietary deal dataset[4]
Evaluate Pharma
Commercial deal/patent intelligence described[1]
AI grounding
Assyro Intelligence
Answers grounded in supported public records[4]
Evaluate Pharma
Ask Ella uses licensed product data[2]
Other Evaluate applications
Assyro Intelligence
No proprietary commercial portfolio dataset[4]
Evaluate Pharma
Separate product/data scope must be named[2][3]
Commercial terms
Assyro Intelligence
Free start; custom team pricing with unlimited users[4][5]
Evaluate Pharma
Tailored product/data package; confirm Ella entitlement[2][3]

Assyro Intelligence and Evaluate Pharma: feature comparison
Capability	Assyro Intelligence	Evaluate Pharma
Public regulatory/company evidence	Supported source-cited research[4]	Qualify underlying events in the licensed product[1]
Consensus commercial forecasts	Proprietary consensus forecasts are not offered[4]	Named Evaluate Pharma forecast dataset[1]
Deal and patent benchmarks	Public disclosures only; no proprietary deal dataset[4]	Commercial deal/patent intelligence described[1]
AI grounding	Answers grounded in supported public records[4]	Ask Ella uses licensed product data[2]
Other Evaluate applications	No proprietary commercial portfolio dataset[4]	Separate product/data scope must be named[2][3]
Commercial terms	Free start; custom team pricing with unlimited users[4][5]	Tailored product/data package; confirm Ella entitlement[2][3]

Product details and recommendations reflect publicly available information and our own assessment as of October 2026, provided for comparison. Evaluate Pharma is a product of Evaluate; trademarks belong to their respective owners.

Which one should you choose?

Choose Assyro Intelligence if

You need to verify an approval, trial update or disclosed company event.
Public evidence and your team's analysis meet the research requirement.
You want to monitor identified regulatory or clinical sources.

Choose Evaluate Pharma if

Consensus sales forecasts are a necessary decision input.
Commercial deal or asset benchmarks belong in the purchase.
Ask Ella's licensed data scope matches the proposed research workflow.

The detailed comparison

Is the number a fact, disclosure or forecast?

Assyro Intelligence

Identify the original filing/record and date. Separate a company's statement from an authority event or your inference. Public research does not manufacture a proprietary consensus estimate.

Evaluate Pharma

Retain forecast vintage, horizon, currency, geography and aggregation assumptions. Compare a prior forecast with a later revision without presenting either as realized sales. A citation supports traceability, not future accuracy.

[1][4]

Which licensed dataset does the assistant actually query?

Assyro Intelligence

Qualify supported public sources and missing evidence for the question. Do not infer access to an Evaluate dataset from an overlapping asset name.

Evaluate Pharma

Ask Ella's current FAQ names Evaluate Pharma and Biomedtracker availability and distinguishes Ella from Norstella Atlas CI. Confirm your subscription and underlying record scope; a related product's data is not automatically included.

[2]

Price the licensed data and permitted output use

Request product/dataset, geography, forecast history, access, Ella, export/feed, sharing and service terms. Name separately required products in the proposal; do not price the entire portfolio from one dataset description.

Match Assyro to the public-research portion it can serve. Include entity reconciliation, analyst review, model-assumption documentation, monitoring and retained evidence. No matched proposal supports a generic savings or ROI claim.

[2][3][5]

A forecast-and-event evidence pilot

Record asset/indication, data type, vintage, geography, currency, source, assumptions and reviewer disposition.

Historical vintage

Retrieve a prior forecast and later revision. Preserve both dates and explain the changed estimate.

Metric ambiguity

Ask an unqualified sales question and require currency, geography, period and forecast-versus-actual clarification.

Public event

Verify an approval or disclosed milestone from its original record and keep its implications separate.

Entitlement and sharing

Ask for a record outside the subscription, inspect the unresolved response and confirm what output may be shared or retained.

Where Evaluate Pharma is stronger

No tool wins on everything. Here is where Evaluate Pharma is the better choice today.

A commercial consensus-forecast dataset beyond Assyro's public-source research.
Published deal, patent and asset-benchmarking scope for commercial teams.
An assistant grounded in the specifically licensed product records.

Adopting Assyro Intelligence

Public evidence can complement commercial forecasts, but does not replace the proprietary dataset. Check reuse and retention rights before moving forecast tables, model outputs or assistant responses into another system. No cross-vendor synchronization is established.

1Inventory recurring questions, forecast vintages, asset identifiers and licensed exports.
2Check sharing, retention and downstream processing rights.
3Separate public-event facts from forecasts and commercial assumptions.
4Run an overlapping public-question sample and reconcile identifiers/dates.
5Assign monitoring owners and retain the forecast product where the decision requires its data.

Sources and evidence

Product documents establish published scope. Evaluation scenarios and recommendations are Assyro's analysis. Confirm availability, configuration and contract scope with each vendor.

Evaluate Pharma
Current consensus forecasts, deal/patent and commercial intelligence scope; checked October 13, 2026; no revision displayed
Ask Ella and product entitlement FAQ
Licensed-product grounding, Pharma/Biomedtracker availability and distinction from Atlas CI; checked October 13, 2026
Evaluate pricing
Current tailored package and product/data scope; checked October 13, 2026; exact proposal still required
Assyro Intelligence product scope
Published product definition and capability scope; checked October 13, 2026; related applications require their own quoted scope
Assyro pricing
Published custom pricing and unlimited users on every plan; checked October 13, 2026; no competitor price advantage inferred